European study shows that prevention in patients with inherited cancer risks produces substantial cost benefits
A European study indicates that early genetic screening for Li-Fraumeni syndrome is significantly more cost-effective than treating the resulting cancers. Researchers found that prevention costs are roughly nine times lower than treatment costs for patients with TP53 gene alterations.
Why it matters
This research provides a strong economic argument for integrating genetic testing into public health policies to improve patient outcomes and reduce healthcare spending.
edited by Sadie Harley , reviewed by Robert Egan
The article reports on scientific findings using objective data and expert attribution.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in